THE SYNTHESIS OF THIENOTRIAZOLOTHIAZEPINES

Hitoshi Nagaoka, Hiromu Hara, and Toshiyasu Mase*

Central Research Laboratories, Yamanouchi Pharmaceutical Co. Ltd.,
21 Miyukigaoka, Tsukuba, Ibaraki 305, Japan

Abstract—Some derivatives of thienotriazolothiazepine, a novel heteroaepine, were synthesized. These compounds showed anti-PAF activity.

In 1986, WEB-2086 (1), which is characterized by its thienotriazolodiazepine skelton, was reported to exhibit anti-PAF (platelet activating factor) activity. Following this report, a number of thienotriazolodiazepine derivatives have been synthesized and tested for their anti-PAF activity.

In a search for potent and orally active PAF antagonists, we were interested in this structure and planed to synthesize its structurally related analogue, thienotriazolothiazepines (2). While some benzotriazolothiazepines (3) have been reported, there have, to the best of our knowledge, been no report on the synthesis of thienotriazolothiazepines. Now, we report the first synthesis of thienotriazolothiazepines.

Synthetic route is shown in Scheme I. First, the α-cyanoketone (4) was treated with 1,4-dithiane-2,5-diol and Et$_3$N or 1-butanal, sulfur and Et$_3$N to give the 2-aminothiophene (5a, 49%) or its ethyl analogue (5b, 57%), respectively. Protection of the amino group of 5 with t-butoxycarbonyl (Boc) group (6a: 63%, 6b: 64%) followed by reduction (NaBH$_4$, DMF) furnished the alcohols (7a: 88%, 7b: 76%).
Scheme I

a) 1,4-dithiane-2,5-diol, Et$_3$N, dioxane, b) I-butanal, sulfur, Et$_3$N, 

10%NaOH q., MF,

c) Boc$_2$O, 10%NaOH aq., THF, d) NaH, Boc$_2$O, DMF, e) NaBH$_4$, DMF,

f) PPh$_3$, DEAD, ethyl thiglycolate, benzene, g) 10%NaOH aq., MeOH, 

h) (COCl)$_2$, DMF, CH$_2$Cl$_2$, i) (COCl)$_2$, DMF, CH$_2$Cl$_2$ then TFA,

j) Lawesson's reagent, toluene, k) H$_2$NNHzH$_2$O, THF, l) MeC(OMe)$_3$,

m) Br$_2$, pyridine
The alcohols (7) were treated under Mitsunobu conditions (Ph$_3$P, DEAD, ethyl thioglycolate, benzene) to provide the sulfides (8a: 35%, 8b: 68%), which were hydrolyzed to give the carboxylic acids (9a: 97%, 9b: 92%).

Now that we obtained the desired precursor for the thiazepine ring, the stage was set for the cyclization. Cyclization of 9 to the thiazepine (10) was effected by treatment with oxalyl chloride (10a: 14%) or with oxalyl chloride and trifluoroacetic acid (10b: 67%).

The construction of the triazole ring was readily performed under the conventional conditions. Treatment of 10 with Lawesson's reagent gave the thioamide (11a: 97%, 11b: 77%). At last, 11 was converted into the thienotriazolothiazepine (2a: 37%, 2b: 47%) by the successive treatment with hydrazine monohydrate and trimethyl orthoacetate. In the same manner, the bromide (2c) was obtained in 57% yield from 11c, which was prepared from 11a by bromination (Br$_2$, pyridine: 95%).

Thienotriazolothiazepines (2) were tested for their activity in inhibiting rabbit platelet aggregation induced by PAF. All compounds synthesized here exhibited anti-PAF activity (Table1).

Thus we achieved a synthesis of a novel heteroazepine, thienotriazolothiazepines, which showed anti-PAF activity.

ACKNOWLEDGEMENTS

We are indebted to Drs. N. Inukai and K. Murase for their encouragements. We are also grateful to the members of the Physico-Analitical Center in their laboratories for the measurements of nmr and mass spectra. Finally, we would like to express our thanks to the members of the Department of Pharmacology in their laboratories for the measurements of anti-PAF activity.

**Table 1. Inhibition of PAF(10^{-8}M)-induced Platelet Aggregation in Rabbit P.R.P.**

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC$_{50}$(10^{-6}M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2a</td>
<td>21</td>
</tr>
<tr>
<td>2b</td>
<td>(42%)*</td>
</tr>
<tr>
<td>2c</td>
<td>26</td>
</tr>
</tbody>
</table>

* Inhibition of platelet aggregation at the concentration of 10^{-8}M
REFERENCES AND NOTES


6) Bromination (Br₂, Ph₃P or NBS, Ph₃P) or mesylation (MsCl, Et₃N) of 4a failed, presumably because of the lability of the product.


8) 2a, ¹H Nmr (100 MHz, CDCl₃, TMS)δ: 2.43 (3H, s), 3.83 (1H, d, J=14Hz), 3.95 (1H, d, J=14Hz), 5.73 (1H, s), 6.35 (1H, d, J=6Hz), 6.76 (1H, d, J=6Hz), 7.17-7.42 (3H, m), 7.55-7.67 (1H, m); ms m/z: 333 (M⁺).

2b: ¹H Nmr (100MHz, CDCl₃, TMS)δ: 1.30 (3H, t, J=8Hz), 2.39 (3H, s), 2.80 (2H, q, J=8Hz), 3.94 (1H, d, J=14Hz), 3.98 (1H, d, J=14Hz), 5.64 (1H, s), 6.39 (1H, s), 7.19-7.40 (3H, m), 7.48-7.61 (1H, s); ms m/z: 361 (M⁺).

2c: ¹H Nmr (100MHz, CDCl₃, TMS)δ: 2.39 (3H, s), 3.90 (1H, d, J=20Hz), 3.93 (1H, d, J=20Hz), 5.69 (1H, s), 6.74 (1H, s), 7.19-7.36 (3H, m), 7.48-7.64 (1H, m); ms m/z: 413(M⁺).


Received, 14th May, 1990